-
Palobiofarma announces significant advances in the clinical development of PBF-999 for Prader-Willi Syndrome
Read more: Palobiofarma announces significant advances in the clinical development of PBF-999 for Prader-Willi SyndromePamplona, Spain – May 11st, 2026 – Palobiofarma S.L., a biopharmaceutical company focused on the discovery and development of innovative treatments for orphan diseases, today announced significant progress in the clinical development of PBF‑999, its novel PDE10 inhibitor for the…
-
Palobiofarma announce several important milestones dealing with the clinical development of PBF-999 for Prader-Willi Syndrome
Read more: Palobiofarma announce several important milestones dealing with the clinical development of PBF-999 for Prader-Willi Syndrome[Pamplona, Spain], October 27, 2025 – Palobiofarma S.L., a biopharmaceutical company dedicated to the discovery and development of innovative drugs for orphan diseases, announced today the achievement of several important milestones in the clinical development of PBF-999, a novel PDE10…
-
Palobiofarma Announces Completion of Dual A2A/H3 Receptor Antagonist Research Project for Parkinson’s Disease
Read more: Palobiofarma Announces Completion of Dual A2A/H3 Receptor Antagonist Research Project for Parkinson’s DiseaseNavarra, Spain – August 28, 2025 — Palobiofarma is pleased to announce the successful completion of the industrial research project titled “Investigation of Dual Antagonist Compounds Targeting A2A and H3 Receptors for the Treatment of Parkinson’s Disease” (Project Code: 0011-1365-2023-000003), co-funded by…
-
Palobiofarma and Medibiofarma open new headquarters in the AIN building in Cordovilla, Spain
Read more: Palobiofarma and Medibiofarma open new headquarters in the AIN building in Cordovilla, SpainPalobiofarma and Medibiofarma open new headquarters in the AIN building in Cordovilla, Spain Pamplona-Iruña, February 27, 2025 – The Navarra biotechnology companies, Palobiofarma and Medibiofarma, celebrated the inauguration of their new headquarters in the building of the Industry Association of…
-
PAMPLONA, SPAIN, SEPTEMBER 9th, 2024—Palobiofarma is pleased to announce today positive top-line results in a Phase 2 trial of the novel oral drug PBF-680 in patients with moderate-to-severe COPD.
Read more: PAMPLONA, SPAIN, SEPTEMBER 9th, 2024—Palobiofarma is pleased to announce today positive top-line results in a Phase 2 trial of the novel oral drug PBF-680 in patients with moderate-to-severe COPD.Palobiofarma S.L. Announces Positive Top-Line Results from the Phase 2 Trial of Oral PBF-680 in Moderate-to-Severe COPD patients. Primary endpoint was achieved, with PBF-680 demonstrating a statistically significant reduction in blood eosinophil count over 4 weeks Reduction in blood eosinophil…
-
Palobiofarma announces the completion the Phase II clinical trial with its investigational therapy PBF-680 in chronic obstructive pulmonary disease (COPD) patients.
Read more: Palobiofarma announces the completion the Phase II clinical trial with its investigational therapy PBF-680 in chronic obstructive pulmonary disease (COPD) patients.Pamplona, Spain – Palobiofarma S.L. is pleased to announce the “last patient last visit” of the Phase II trial investigating the safety and preliminary efficacy of PBF-680 in moderate to severe COPD patients. The trial has recruited 104 patients in…
-
PBF-999, the first in class treatment in development for the Prader-Willi Syndrome has received “Orphan Drug Designation” by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA).
Read more: PBF-999, the first in class treatment in development for the Prader-Willi Syndrome has received “Orphan Drug Designation” by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA).Pamplona, Spain – Palobiofarma S.L. is pleased to announce that the FDA and the EMA have granted Orphan Drug Designation to our novel therapeutic candidate, PBF-999, for the treatment of Prader-Willi Syndrome (PWS). These designations represent a significant milestone in…
-
Palobiofarma closes a €7M round with the participation of Inveready, Sodena and the Promotor team
Read more: Palobiofarma closes a €7M round with the participation of Inveready, Sodena and the Promotor teamPamplona-Iruña, February 2, 2024.- Palobiofarma has closed a seven-million-euro investment round led by Inveready, through the Inveready Biotech IV fund, the public company Sodena and the company’s founders. The investment will be used to complete three phase II clinical trials…
-
Palobiofarma S.L. Receives Rare Pediatric Disease Designation from the U.S. FDA for PBF-999 for the Treatment of Prader-Willi Syndrome
Read more: Palobiofarma S.L. Receives Rare Pediatric Disease Designation from the U.S. FDA for PBF-999 for the Treatment of Prader-Willi SyndromePamplona, Spain November 6, 2023 Palobiofarma S.L. announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the company’s phosphodiesterase 10 (PDE-10) inhibitor, PBF-999, for the treatment of patients with Prader-Willi Syndrome (PWS). “Pediatric patients living…
-
Palobiofarma announces the enrolment of the first three patients in the clinical study investigating the effects of its novel compound PBF-999 for the treatment of Prader-Willi Syndrome
Read more: Palobiofarma announces the enrolment of the first three patients in the clinical study investigating the effects of its novel compound PBF-999 for the treatment of Prader-Willi Syndrome[Pamplona, Spain], [May 9th, 2023] – Palobiofarma S.L., a biopharmaceutical company dedicated to the discovery and development of innovative drugs, has enrolled the first three patients in a clinical study to investigate the potential of PBF-999, a novel PDE10 inhibitor,…
